



OPEN ACCESS

EDITED AND REVIEWED BY
Cristiana Cairo,
University of Maryland, United States

*CORRESPONDENCE

Daniela Wesch

✉ daniela.wesch@uksh.de

Christoph Baumann

✉ christoph.baumann@evobright.com

[†]These authors have contributed
equally to this work and share
first authorship

RECEIVED 23 July 2025

ACCEPTED 29 August 2025

PUBLISHED 12 September 2025

CITATION

Oberg H-H, Deseke M, Krohn S,
Winterberg D, Peipp M, Bauerschlag D,
Künkele K-P, Wesch D and Baumann C (2025)
Correction: Tumor-restricted activation of
V γ 9V δ 2 T cells via bispecific Evobodies: a
novel strategy for safe and potent
immunotherapy in ovarian cancer.
Front. Immunol. 16:1672018.
doi: 10.3389/fimmu.2025.1672018

COPYRIGHT

© 2025 Oberg, Deseke, Krohn, Winterberg,
Peipp, Bauerschlag, Künkele, Wesch and
Baumann. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Correction: Tumor-restricted activation of V γ 9V δ 2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer

Hans-Heinrich Oberg^{1†}, Malte Deseke^{2†}, Steffen Krohn^{3†},
Dorothee Winterberg³, Matthias Peipp³, Dirk Bauerschlag⁴,
Klaus-Peter Künkele², Daniela Wesch^{1*}
and Christoph Baumann^{2*}

¹Institute of Immunology, University Hospital Schleswig-Holstein, Kiel, Germany, ²Evobright GmbH, Vienna, Austria, ³Division of Antibody-Based Immunotherapy, University Hospital Schleswig-Holstein and Christian-Albrechts University, Kiel, Germany, ⁴Polyclinic and Clinic of Gynecology, University Center, Jena, Germany

KEYWORDS

V γ 9V δ 2 T cells, FOLR1, evobody, ovarian cancer, immunotherapy, BTN3A

A Correction

Tumor-restricted activation of V γ 9V δ 2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer

By Oberg H-H, Deseke M, Krohn S, Winterberg D, Peipp M, Bauerschlag D, Künkele K-P, Wesch D and Baumann C (2025) *Front. Immunol.* 16:1628501. doi: 10.3389/fimmu.2025.1628501

In the published article, there was a mistake in the **Materials and methods** section. In the paragraph, **Establishment of V γ 9V δ 2 T cell lines**, there was an erroneous concentration of 2.5mM:

“Peripheral blood lymphocytes (PBL) were isolated from leukocyte concentrates or EDTA blood of healthy or ovarian cancer patient donors using Ficoll-Hypaque™ PLUS (Cytiva) density gradient centrifugation. A total of 1×10^6 PBMCs were stimulated with 2.5 mM of the aminobisphosphonate (n-BP) zoledronate (Novartis, Basel, Switzerland) in complete medium.

The complete culture medium for primary immune cell culture or assay setup was composed of RPMI 1640 supplemented with 2 mM L-glutamine, 25 mM HEPES, 100 U/mL penicillin, 100 μ g/mL streptomycin, and 10% FCS. All cell culture procedures and assay incubation steps were performed at 37°C in a humidified atmosphere with 5% CO₂. Activation of PBL with n-BP and IL-2 induced selective activation and proliferation of V γ 9V δ 2 T cells. Recombinant IL-2 (Novartis) was added every 2 days at a concentration of 50 IU/mL for 14 days, as initially stimulated $\gamma\delta$ T cells produced only low levels of IL-2. After 14 days, the short-term activated $\gamma\delta$ T cell lines were stained with the following

antibodies: AF700-labeled anti-CD3 clone SK7 (BioLegend, San Diego, CA, USA); AF488-labeled anti-V γ 9 clone 7A5 (62) flow cytometry to determine purity. $\gamma\delta$ T cells with a purity of >95% were used for functional assays”.

A correction has been made to the section **Materials and methods, Establishment of V γ 9V δ 2 T cell lines:**

“Peripheral blood lymphocytes (PBL) were isolated from leukocyte concentrates or EDTA blood of healthy or ovarian cancer patient donors using Ficoll-Hypaque™ PLUS (Cytiva) density gradient centrifugation. A total of 1×10^6 PBMCs were stimulated with 2.5 μ M of the aminobisphosphonate (n-BP) zoledronate (Novartis, Basel, Switzerland) in complete medium.

The complete culture medium for primary immune cell culture or assay setup was composed of RPMI 1640 supplemented with 2 mM L-glutamine, 25 mM HEPES, 100 U/mL penicillin, 100 μ g/mL streptomycin, and 10% FCS. All cell culture procedures and assay incubation steps were performed at 37°C in a humidified atmosphere with 5% CO₂. Activation of PBL with n-BP and IL-2 induced selective activation and proliferation of V γ 9V δ 2 T cells. Recombinant IL-2 (Novartis) was added every 2 days at a concentration of 50 IU/mL for 14 days, as initially stimulated $\gamma\delta$ T cells produced only low levels of IL-2. After 14 days, the short-term activated $\gamma\delta$ T cell lines were stained with the following antibodies: AF700-labeled anti-CD3 clone SK7 (BioLegend, San Diego, CA, USA); AF488-labeled anti-V γ 9 clone 7A5 (62) flow cytometry to determine purity. $\gamma\delta$ T cells with a purity of >95% were used for functional assays”.

“A correction was also made to the **Results** section, **Evobodies are first-in-class bispecific therapeutic antibodies that mimic an intracellular infection selectively at the tumor site:**

This sentence was altered in error: “Comparing the cytotoxic responses of each candidate molecule against OVCAR-3 wild-type (WT) and FOLR1 KO cells allowed us to determine the respective therapeutic windows. window was determined.”

A correction has been made to the sentence: “Comparing the cytotoxic responses of each candidate molecule against OVCAR-3 wild-type (WT) and FOLR1 KO cells allowed us to determine the respective therapeutic window was determined.”

Additionally, a final error was made in the **Results** section, **Evobodies mediate V γ 9V δ 2 T cell cytotoxicity against autologous ovarian tumor cells:**

Part of this sentence was made redundant: “Understandably, for more than three decades V γ 9V δ 2 T cells have attracted the interest of many researchers and drug developers for over three decades (23).”

This sentence has now been corrected: “Understandably, V γ 9V δ 2 T cells have attracted the interest of many researchers and drug developers for over three decades (23).”

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.